phrykt

BeOne Medicines Ltd. (ONC): who owns it and who trades it

As of Nov 16, 2026, ONC insiders reported 205 open-market sales worth $386M and no purchases in the last 12 months, with 97% of the sale value made under pre-set 10b5-1 plans. The largest seller was John Oyler (CEO), with $328M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling BeOne Medicines

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ONC

279 funds and institutions reported ONC shares worth $9.9B at the end of Q2 2026, about 2% of the company. The largest holder is Baker Bros. Advisors LP with 0.6%.

Funds and institutions (13F) 2%Everyone else 98%

10 largest owners, by share of the company

Baker Bros. Advisors LP0.6%
Primecap Management Co0.3%
Capital International Investors0.3%
FMR LLC (Fidelity)0.2%
Capital World Investors0.2%
Citadel Advisors LLC0.1%
Temasek Holdings (Private) Ltd0.1%
T. Rowe Price Associates0.1%
BlackRock, Inc.0.0%
Millennium Management LLC0.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Baker Bros. Advisors LP8.80M0.61%$2.5BNo change
Primecap Management Co5.01M0.35%$1.4B+1%
Capital International Investors4.21M0.29%$1.2B+1%
FMR LLC (Fidelity)2.48M0.17%$706M-33%
Capital World Investors2.25M0.16%$641M+39%
Citadel Advisors LLC1.43M0.10%$406M+38%
Temasek Holdings (Private) Ltd845,7290.06%$241M-2%
T. Rowe Price Associates758,7520.05%$216M+41%
BlackRock, Inc.694,6180.05%$198M+6%
Millennium Management LLC543,3230.04%$155M+165%
Morgan Stanley497,4370.03%$142M+7%
Siren, L.L.C.465,0000.03%$133MNo change
Bank of America Corp439,3360.03%$125M+8%
Baird Financial Group, Inc.368,9780.03%$105M+6%
Man Group plc307,4630.02%$87.6M+27%
Capital International, Inc.305,4770.02%$87.1M+1%
Candriam S.C.A.289,7350.02%$82.5M+12%
Two Sigma Investments, LP286,5520.02%$81.7M+754%
UBS Group AG258,5890.02%$73.7M-38%
Arrowstreet Capital, Limited Partnership249,7580.02%$71.2M+126%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ONC insiders reported $0 of open-market purchases and $386M of sales. 97% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$386M
205 trades, 12 people
Sales under a 10b5-1 plan
97%
Share of sale value
Latest trade
Nov 6, 2026
Filed Nov 10, 2026

Purchases and sales by month

$208M$208MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 6, 2026Titus B. BallPrincipal Accounting OffSale1,533$405.55$622KForm 4
Nov 6, 2026Titus B. BallPrincipal Accounting OffSale26$406.34$10.6KForm 4
Nov 5, 2026Chan Henry LeeVice presidentSale plan660$400.00$264KForm 4
Nov 5, 2026Chan Henry LeeVice presidentSale plan455$402.00$183KForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan880$355.56$313KForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan1,440$355.62$512KForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan1,239$357.54$443KForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan1,681$358.75$603KForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan1,280$359.72$460KForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan320$360.64$115KForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan2,331$362.35$845KForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan8,148$363.24$3MForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan2,841$363.95$1MForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan3,965$365.43$1.4MForm 4
Oct 27, 2026Xiaodong WangDirectorSale plan6,903$366.22$2.5MForm 4
Oct 13, 2026Xiaodong WangDirectorSale plan7,167$349.56$2.5MForm 4
Oct 13, 2026Xiaodong WangDirectorSale plan10,361$350.47$3.6MForm 4
Oct 13, 2026Xiaodong WangDirectorSale plan5,681$351.40$2MForm 4
Oct 13, 2026Xiaodong WangDirectorSale plan6,558$352.57$2.3MForm 4
Oct 13, 2026Xiaodong WangDirectorSale plan1,260$353.24$445KForm 4
Sep 30, 2026Chan Henry LeeVice presidentSale plan1,115$375.00$418KForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan160$356.97$57.1KForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan120$358.71$43KForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan40$359.16$14.4KForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan2,241$361.05$809KForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan738$367.23$271KForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan3,499$363.10$1.3MForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan3,419$364.07$1.2MForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan2,047$365.85$749KForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan14,525$366.58$5.3MForm 4
Sep 28, 2026Xiaodong WangDirectorSale plan4,239$362.17$1.5MForm 4
Sep 8, 2026Xiaodong WangDirectorSale plan10,688$349.28$3.7MForm 4
Sep 8, 2026Xiaodong WangDirectorSale plan7,492$348.31$2.6MForm 4
Sep 8, 2026Xiaodong WangDirectorSale plan1,181$345.38$408KForm 4
Sep 8, 2026Xiaodong WangDirectorSale plan6,569$350.27$2.3MForm 4
Sep 8, 2026Xiaodong WangDirectorSale plan1,721$348.01$599KForm 4
Sep 8, 2026Xiaodong WangDirectorSale plan1,517$347.39$527KForm 4
Sep 8, 2026Xiaodong WangDirectorSale plan2,841$346.16$983KForm 4
Sep 8, 2026Xiaodong WangDirectorSale plan6,278$351.25$2.2MForm 4
Sep 1, 2026Titus B. BallPrincipal Accounting OffSale132$355.86$47KForm 4
Aug 25, 2026Xiaobin WuPresidentSale plan280$380.00$106KForm 4
Aug 12, 2026John OylerCEOSale plan14,102$359.12$5.1MForm 4
Aug 12, 2026John OylerCEOSale plan1,980$354.71$702KForm 4
Aug 12, 2026John OylerCEOSale plan2,515$356.43$896KForm 4
Aug 12, 2026John OylerCEOSale plan15,396$357.63$5.5MForm 4
Aug 12, 2026John OylerCEOSale plan20,899$358.41$7.5MForm 4
Aug 11, 2026Chan Henry LeeVice presidentSale plan2,666$360.00$960KForm 4
Aug 11, 2026John OylerCEOSale plan13,695$359.32$4.9MForm 4
Aug 11, 2026John OylerCEOSale plan8,081$360.33$2.9MForm 4
Aug 11, 2026John OylerCEOSale plan14,569$361.47$5.3MForm 4
Aug 11, 2026John OylerCEOSale plan11,568$362.34$4.2MForm 4
Aug 11, 2026John OylerCEOSale plan13,403$363.45$4.9MForm 4
Aug 11, 2026John OylerCEOSale plan5,211$364.31$1.9MForm 4
Aug 11, 2026John OylerCEOSale plan3,176$365.26$1.2MForm 4
Aug 11, 2026John OylerCEOSale plan1,200$366.31$440KForm 4
Aug 11, 2026John OylerCEOSale plan4$367.00$1.5KForm 4
Aug 10, 2026John OylerCEOSale plan67$350.00$23.4KForm 4
Aug 10, 2026John OylerCEOSale plan3,673$353.32$1.3MForm 4
Aug 10, 2026John OylerCEOSale plan6,717$354.78$2.4MForm 4
Aug 10, 2026John OylerCEOSale plan3,476$355.66$1.2MForm 4
Aug 10, 2026John OylerCEOSale plan12,418$356.62$4.4MForm 4
Aug 10, 2026John OylerCEOSale plan15,869$357.67$5.7MForm 4
Aug 10, 2026John OylerCEOSale plan45,044$358.70$16.2MForm 4
Aug 10, 2026John OylerCEOSale plan21,254$359.50$7.6MForm 4
Aug 10, 2026John OylerCEOSale plan3,680$360.63$1.3MForm 4
Aug 10, 2026John OylerCEOSale plan2,813$351.80$990KForm 4
Aug 3, 2026Aaron RosenbergCFOSale1,157$312.72$362KForm 4
Jul 30, 2026Chan Henry LeeVice presidentSale1,044$323.69$338KForm 4
Jul 22, 2026Chan Henry LeeVice presidentSale plan1,669$325.00$542KForm 4
Jul 21, 2026John OylerCEOSale plan15,379$316.26$4.9MForm 4
Jul 21, 2026John OylerCEOSale plan20,029$316.91$6.3MForm 4
Jul 21, 2026John OylerCEOSale plan7,842$318.41$2.5MForm 4
Jul 21, 2026John OylerCEOSale plan15,807$319.29$5MForm 4
Jul 21, 2026John OylerCEOSale plan2,340$320.06$749KForm 4
Jul 20, 2026John OylerCEOSale plan15,499$312.29$4.8MForm 4
Jul 20, 2026John OylerCEOSale plan14,326$312.96$4.5MForm 4
Jul 20, 2026John OylerCEOSale plan1,850$313.91$581KForm 4
Jul 20, 2026John OylerCEOSale plan1,512$315.26$477KForm 4
Jul 20, 2026John OylerCEOSale plan523$316.14$165KForm 4
Jul 20, 2026John OylerCEOSale plan280$318.30$89.1KForm 4
Jul 20, 2026John OylerCEOSale plan5,146$310.08$1.6MForm 4
Jul 20, 2026John OylerCEOSale plan2,907$311.80$906KForm 4
Jul 20, 2026John OylerCEOSale plan6,273$310.75$1.9MForm 4
Jul 17, 2026John OylerCEOSale plan1,440$305.20$439KForm 4
Jul 17, 2026John OylerCEOSale plan597$306.96$183KForm 4
Jul 17, 2026John OylerCEOSale plan680$309.05$210KForm 4
Jul 17, 2026John OylerCEOSale plan4,833$310.37$1.5MForm 4
Jul 17, 2026John OylerCEOSale plan35,829$312.17$11.2MForm 4
Jul 17, 2026John OylerCEOSale plan14,915$313.19$4.7MForm 4
Jul 17, 2026John OylerCEOSale plan740$314.32$233KForm 4
Jul 17, 2026John OylerCEOSale plan51$315.06$16.1KForm 4
Jul 17, 2026John OylerCEOSale plan5,543$311.42$1.7MForm 4
Jul 16, 2026John OylerCEOSale plan42,798$317.79$13.6MForm 4
Jul 16, 2026John OylerCEOSale plan32,224$316.82$10.2MForm 4
Jul 16, 2026John OylerCEOSale plan15,097$319.99$4.8MForm 4
Jul 16, 2026John OylerCEOSale plan20,505$321.00$6.6MForm 4
Jul 16, 2026John OylerCEOSale plan13,109$321.61$4.2MForm 4
Jul 16, 2026John OylerCEOSale plan1,560$322.71$503KForm 4
Jul 16, 2026John OylerCEOSale plan520$323.59$168KForm 4
Jul 16, 2026John OylerCEOSale plan233$311.98$72.7KForm 4

Latest 100 of 205 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
John OylerChief Executive Officer, Director–$328MAug 12, 2026
Xiaodong WangDirector–$46.8MOct 27, 2026
Chan Henry LeeSVP, General Counsel–$4.7MNov 5, 2026
Xiaobin WuPresident and COO–$2.9MAug 25, 2026
Lai WangPresident, Global Head of R&D–$1.2MJun 23, 2026
Corazon (Corsee) D. SandersDirector–$961KMay 22, 2026
Titus B. BallPrincipal Accounting Officer–$760KNov 6, 2026
Aaron RosenbergChief Financial Officer–$524KAug 3, 2026
Baker Bros. Advisors LpDirector–$131KMay 22, 2026
Margaret DuganDirector–$65.6KMay 22, 2026
Alessandro RivaDirector–$65.6KMay 22, 2026
Qingqing YiDirector–$65.6KJun 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ONC short interest

Low short interest. 0.1% of ONC shares are sold short: about 1 share in 927. Over the last 12 reports the number of shares short went up 53%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.60M ONC shares were sold short, 0.1% of the shares outstanding, down 10.6% from the report before. At the average daily volume of 366,722 shares, buying them all back would take about 4.4 trading days (days to cover).

Shares short, % of all shares

0.11%May 15Oct 300.14%

Days to cover

4.4May 15Oct 305.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.60M0.11%-11%366,7224.4
Oct 15, 20261.79M0.12%-7%367,8964.9
Sep 30, 20261.93M0.13%+13%389,4515.0
Sep 15, 20261.71M0.12%+20%378,4734.5
Aug 31, 20261.42M0.10%+11%341,6894.2
Aug 14, 20261.28M0.09%+45%455,7982.8
Jul 31, 2026880,6270.06%-5%372,5202.4
Jul 15, 2026926,9860.06%+17%352,6962.6
Jun 30, 2026791,5770.05%-12%296,4082.7
Jun 15, 2026902,3920.06%-17%311,6222.9
May 29, 20261.09M0.08%+4%222,5774.9
May 15, 20261.05M0.07%-6%252,3484.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

BeOne Medicines company events

BeOne Medicines filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 26, 2026ResultsReleased financial results. Filing
  3. Aug 5, 2026ResultsReleased financial results. Filing
  4. Jun 26, 2026AnnouncementAs previously disclosed in the Quarterly Report on Form 10-Q filed by BeOne Medicines Ltd. with the Securities and Exchange Commission on May 6, 2026, the Company is subject to ongoing tax audits that may result in liabilities which could be materially different from current estimates due to the… Filing
  5. Jun 11, 2026LeadershipAs previously disclosed in the definitive proxy statement for the 2026 Annual General Meeting of Shareholders of BeOne Medicines Ltd. filed with the U.S. Securities and Exchange Commission on April 28, 2026, Mr. Michael Goller, Mr. Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders and Mr. Qingqing… Filing
  6. May 15, 2026AnnouncementBeOne Medicines Ltd. announced that BEQALZI™ (sonrotoclax) has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, after at least two lines of systemic therapy, including a Bruton’s tyrosine… Filing
  7. May 6, 2026ResultsReleased financial results. Filing
  8. Apr 14, 2026ResultsReleased financial results. Filing
  9. Feb 26, 2026ResultsReleased financial results. Filing
  10. Dec 19, 2025AgreementEnded an important agreement. Filing
  11. Dec 18, 2025LeadershipBeOne Medicines Ltd. appointed Dr. Lai Wang to serve as President, Global Head of Research and Development of the Company. Filing
  12. Nov 19, 2025AgreementEntry into Facilities Agreement On November 13, 2025 (November 14, 2025 Hong Kong time), BeOne Medicines Ltd. entered into the Facilities Agreement, by and among (i) certain subsidiaries of the Company listed in the Facilities Agreement, as guarantors, (ii) The Hongkong and Shanghai Banking… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

BeOne Medicines financials

Famous investors that hold ONC

4 of the 50 well-known investors we track reported holding ONC in their latest 13F filing. The largest position is Ken Griffin's, worth $190M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026520,094$190M0.1%-64%
Israel Englander · Millennium ManagementQ3 2026278,720$102M0.1%-49%
Jim Simons · Renaissance TechnologiesQ3 2026139,805$51.2M0.1%+37%
Ken Fisher · Fisher Asset ManagementQ3 20261,002$367K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ONC in the last 120 days.

FiledHolderFormStake
Nov 13, 2026OYLER JOHN13G/A3.6%
Nov 13, 2026OYLER JOHN13G/A3.6%

Questions about BeOne Medicines Ltd. (ONC) stock

Who owns the most ONC stock?

The largest reported owner of BeOne Medicines Ltd. (ONC) is Baker Bros. Advisors LP, with 0.6% of the company. In total, 279 funds and institutions reported holding ONC at the end of Q2 2026, together about 2% of the shares. See the largest owners.

Are ONC insiders buying or selling?

In the last 12 months, ONC insiders reported no open-market purchases and 205 sales worth $386M. The latest trade was on Nov 6, 2026. See every trade.

What is the short interest in ONC?

As of Oct 30, 2026, 1.60M ONC shares were sold short, 0.1% of the shares outstanding, down 10.6% from the report before. At the average daily volume of 366,722 shares, buying them all back would take about 4.4 trading days (days to cover). See the history.

Which famous investors hold ONC?

4 of the 50 well-known investors we track reported ONC in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $190M. See all holders.

Executive pay

BeOne Medicines's chief executive was paid a total of $17.9M for the year ended Dec 31, 2025, down 14% from $20.8M the year before. In the last 12 months, BeOne Medicines's executives and directors bought no stock on the open market and sold $386M.

Chief executive, total pay$17.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$60.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$10.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.